The cell & gene therapy bioanalytical testing services market in the UK is expected to reach a projected revenue of US$ 29.0 million by 2030. A compound annual growth rate of 6.9% is expected of the UK cell & gene therapy bioanalytical testing services market from 2024 to 2030.
HC Outsourcing
Clinical & Non-Clinical Outsourcing Services
Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
UK cell & gene therapy bioanalytical testing services market highlights
The UK cell & gene therapy bioanalytical testing services market generated a revenue of USD 18.2 million in 2023 and is expected to reach USD 29.0 million by 2030.
The UK market is expected to grow at a CAGR of 6.9% from 2024 to 2030.
In terms of segment, bioavailability & bioequivalence studies was the largest revenue generating test type in 2023.
Pharmacokinetics is the most lucrative test type segment registering the fastest growth during the forecast period.
Cell & gene therapy bioanalytical testing services market data book summary
Market revenue in 2023
USD 18.2 million
Market revenue in 2030
USD 29.0 million
Growth rate
6.9% (CAGR from 2023 to 2030)
Largest segment
Bioavailability & bioequivalence studies
Fastest growing segment
Pharmacokinetics
Historical data
2018 - 2022
Base year
2023
Forecast period
2024 - 2030
Quantitative units
Revenue in USD million
Market segmentation
Bioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test type
Key market players worldwide
IQVIA Holdings Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Charles River Laboratories International Inc, Syneos Health, Intertek Group PLC
Other key industry trends
In terms of revenue, UK accounted for 3.6% of the global cell & gene therapy bioanalytical testing services market in 2023.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
In Europe, UK cell & gene therapy bioanalytical testing services market is projected to lead the regional market in terms of revenue in 2030.
Germany is the fastest growing regional market in Europe and is projected to reach USD 27.7 million by 2030.
A key factor driving the market growth is the presence of an independent institute that focuses on therapeutics, as well as leading-edge expertise in cell and gene technologies, such as Stevenage Bioscience Catalyst and The Cell and Gene Therapy Catapult (CGT Catapult).
For example, CGT Catapult is an independent innovation and technology organization dedicated to trying to make a difference in the UK's cell and gene therapy companies. Furthermore, the UK is home to numerous prosperous businesses, top-notch academic institutions, and the CGT Catapult, which is wellpositioned to support market growth.
U.K. Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cell & Gene Therapy Bioanalytical Testing Services Market Outlook will help companies and investors design strategic landscapes.
Bioavailability & Bioequivalence Studies was the largest segment with a revenue share of 35.71% in 2023.
Horizon Databook has segmented the U.K. cell & gene therapy bioanalytical testing services market based on bioavailability & bioequivalence studies, pharmacokinetics, pharmacodynamics, other test type covering the revenue growth of each sub-segment from 2018 to 2030.
A key factor driving the market growth is the presence of an independent institute that focuses on therapeutics, as well as leading-edge expertise in cell and gene technologies, such as Stevenage Bioscience Catalyst and The Cell and Gene Therapy Catapult (CGT Catapult).
For example, CGT Catapult is an independent innovation and technology organization dedicated to trying to make a difference in the UK's cell and gene therapy companies. Furthermore, the UK is home to numerous prosperous businesses, top-notch academic institutions, and the CGT Catapult, which is wellpositioned to support market growth.
U.K. Cell & Gene Therapy Bioanalytical Testing Services Market Indication Outlook (Revenue, USD million , 2018-2030)
Infectious Diseases
Rare Diseases
Oncology
Others
Neurological disorders
U.K. Cell & Gene Therapy Bioanalytical Testing Services Market Test Type Outlook (Revenue, USD million , 2018-2030)
Other test type
Pharmacodynamics
Bioavailability & Bioequivalence Studies
Pharmacokinetics
U.K. Cell & Gene Therapy Bioanalytical Testing Services Market Product Outlook (Revenue, USD million , 2018-2030)
Cell Therapy
Gene-Modified Cell Therapy
Gene Therapy
U.K. Cell & Gene Therapy Bioanalytical Testing Services Market Stage of Development Outlook (Revenue, USD million , 2018-2030)
Clinical
Non-Clinical
Reasons to subscribe to Cell & Gene Therapy Bioanalytical Testing Services Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cell & Gene Therapy Bioanalytical Testing Services Market Outlook databook
Our clientele includes a mix of Cell & Gene Therapy Bioanalytical Testing Services Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.K. Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.K. Cell & Gene Therapy Bioanalytical Testing Services Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.